ELISpot (Enzyme-Linked Immunosorbent Spot) is a widely used technology to assess adaptive immune responses in humans and animals. It’s commonly used to characterize pre-existing immune responses and to monitor the immunogenicity of vaccines and other immune-modulating therapies.
The frequency of antigen-specific cells in response to a variety of stimulations can be quantified. PBMC (peripheral blood mononuclear cells) are stimulated in vitro and analyzed for secretion of analytes such as IFNγ, IL-2 and IL-17.
ImmuneCarta offers customizable ELISpot assays to meet specific needs suited for multi-centric clinical studies. Our team participates in ELISpot proficiency testing programs to ensure harmonization of our assays.
Benefits and Applications
- Screen large numbers of peptide libraries to identify breadth, magnitude and specificity of an immune response
- Obtain information for large scale epitope mapping studies
- Identify peptide-reactive cells that can be further analyzed for phenotype and function using ICS (Intracellular Cytokine Staining)
- Monitor immunogenicity of vaccines and immune modulating therapies
- Identify peptide-specific HLA-class I restriction
Picture showing the frequency of IFNγ-secreting T cells in response to a stimulation
with a pool of peptides specific to CMV, EBV and Influenza (CEF pool)
ELISpot is a key methodology used to define the diversity of immune responses in health and disease or following treatment with immune modulating therapies.
ImmuneCarta uses overlapping peptide pool matrices to rapidly identify immunogenic regions of a protein of interest.
ImmuneCarta’s ELISpot approach identifies immunogenic regions
of proteins using overlapping peptide pool libraries